APO RESEARCH · REPORT
Alpha 1 Antitrypsin Deficiency Treatment
Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.
Product & engineering
Understand the product.
Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.
Selected research
Industry Research
Alpha 1 Antitrypsin Deficiency Treatment Industry Research Report 2026
Market perspective
Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.
Global players of Alpha 1 Antitrypsin Deficiency Treatment include Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, Takeda, Baxter, Grifols, CSL Behring and Kamada Ltd, etc. Top five players occupy for share about 28%. United States is the largest market, with a share about 37%, followed by European Union and China. In terms of product, Augmentation Therapy is the largest segment, with a share over 44%.
Report Scope
Read the full market overview
This report quantifies the global Alpha 1 Antitrypsin Deficiency Treatment market in terms of revenue (US$ million) and, where applicable, service volume (Kiloton), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/Kiloton) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Alpha 1 Antitrypsin Deficiency Treatment.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Alpha 1 Antitrypsin Deficiency Treatment Market by Company
Pfizer
GlaxoSmithKline
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical Industries
Takeda
Baxter
Grifols
CSL Behring
Kamada Ltd
Chiesi Pharmaceuticals
Kedrion Group
Vertex Pharmaceuticals
ProMetic Life Sciences
Alpha 1 Antitrypsin Deficiency Treatment Segment by Indication
Augmentation Therapy
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Diabetes
Other
Alpha 1 Antitrypsin Deficiency Treatment Segment by End Users
COPD
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Diabetes
Alpha 1 Antitrypsin Deficiency Treatment Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Alpha 1 Antitrypsin Deficiency Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Alpha 1 Antitrypsin Deficiency Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Alpha 1 Antitrypsin Deficiency Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Alpha 1 Antitrypsin Deficiency Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Augmentation Therapy
- Cystic Fibrosis(CF)
- Non-CF Bronchiectasis(NCFB)
- Diabetes
- Other
Applications
- COPD
- Cystic Fibrosis(CF)
- Non-CF Bronchiectasis(NCFB)
- Diabetes
Companies covered
- Pfizer
- GlaxoSmithKline
- AstraZeneca
- Boehringer Ingelheim
- Teva Pharmaceutical Industries
- Takeda
- Baxter
- Grifols
- CSL Behring
- Kamada Ltd
- Chiesi Pharmaceuticals
- Kedrion Group
- Vertex Pharmaceuticals
- ProMetic Life Sciences
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Alpha 1 Antitrypsin Deficiency Treatment by Indication
- 2.2.1 Market Value Comparison by Indication (2021 VS 2025 VS 2032)
- 2.2.2 Augmentation Therapy
- 2.2.3 Cystic Fibrosis(CF)
- 2.2.4 Non-CF Bronchiectasis(NCFB)
- 2.2.5 Diabetes
- 2.2.6 Other
- 2.3 Alpha 1 Antitrypsin Deficiency Treatment by End Users
- 2.3.1 Market Value Comparison by End Users (2021 VS 2025 VS 2032)
- 2.3.2 COPD
- 2.3.3 Cystic Fibrosis(CF)
- 2.3.4 Non-CF Bronchiectasis(NCFB)
- 2.3.5 Diabetes
- 2.4 Assumptions and Limitations
3 Alpha 1 Antitrypsin Deficiency Treatment Breakdown Data by Indication
- 3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Indication (2021-2026)
- 3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Indication (2027-2032)
4 Alpha 1 Antitrypsin Deficiency Treatment Breakdown Data by End Users
- 4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by End Users (2021-2026)
- 4.2 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by End Users (2027-2032)
5 Global Growth Trends
- 5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Perspective (2021-2032)
- 5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Growth Trends by Region
- 5.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Region (2021-2026)
- 5.2.3 Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Region (2027-2032)
- 5.3 Alpha 1 Antitrypsin Deficiency Treatment Market Dynamics
- 5.3.1 Alpha 1 Antitrypsin Deficiency Treatment Industry Trends
- 5.3.2 Alpha 1 Antitrypsin Deficiency Treatment Market Drivers
- 5.3.3 Alpha 1 Antitrypsin Deficiency Treatment Market Challenges
- 5.3.4 Alpha 1 Antitrypsin Deficiency Treatment Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Revenue
- 6.1.1 Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Revenue (2021-2026)
- 6.1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Players (2021-2026)
- 6.2 Global Alpha 1 Antitrypsin Deficiency Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Alpha 1 Antitrypsin Deficiency Treatment Head Office and Area Served
- 6.4 Global Alpha 1 Antitrypsin Deficiency Treatment Players, Product Type & Application
- 6.5 Global Alpha 1 Antitrypsin Deficiency Treatment Manufacturers Established Date
- 6.6 Global Alpha 1 Antitrypsin Deficiency Treatment Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032)
- 7.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021-2026)
- 7.4 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032)
- 8.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021-2026)
- 8.4 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032)
- 9.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032)
- 10.2 South America Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021-2026)
- 10.4 South America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032)
- 11.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Pfizer
- 12.1.1 Pfizer Company Information
- 12.1.2 Pfizer Business Overview
- 12.1.3 Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021-2026)
- 12.1.4 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
- 12.1.5 Pfizer Recent Developments
- 12.2 GlaxoSmithKline
- 12.2.1 GlaxoSmithKline Company Information
- 12.2.2 GlaxoSmithKline Business Overview
- 12.2.3 GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021-2026)
- 12.2.4 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
- 12.2.5 GlaxoSmithKline Recent Developments
- 12.3 AstraZeneca
- 12.3.1 AstraZeneca Company Information
- 12.3.2 AstraZeneca Business Overview
- 12.3.3 AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021-2026)
- 12.3.4 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
- 12.3.5 AstraZeneca Recent Developments
- 12.4 Boehringer Ingelheim
- 12.4.1 Boehringer Ingelheim Company Information
- 12.4.2 Boehringer Ingelheim Business Overview
- 12.4.3 Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021-2026)
- 12.4.4 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
- 12.4.5 Boehringer Ingelheim Recent Developments
- 12.5 Teva Pharmaceutical Industries
- 12.5.1 Teva Pharmaceutical Industries Company Information
- 12.5.2 Teva Pharmaceutical Industries Business Overview
- 12.5.3 Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021-2026)
- 12.5.4 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
- 12.5.5 Teva Pharmaceutical Industries Recent Developments
- 12.6 Takeda
- 12.6.1 Takeda Company Information
- 12.6.2 Takeda Business Overview
- 12.6.3 Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021-2026)
- 12.6.4 Takeda Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
- 12.6.5 Takeda Recent Developments
- 12.7 Baxter
- 12.7.1 Baxter Company Information
- 12.7.2 Baxter Business Overview
- 12.7.3 Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021-2026)
- 12.7.4 Baxter Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
- 12.7.5 Baxter Recent Developments
- 12.8 Grifols
- 12.8.1 Grifols Company Information
- 12.8.2 Grifols Business Overview
- 12.8.3 Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021-2026)
- 12.8.4 Grifols Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
- 12.8.5 Grifols Recent Developments
- 12.9 CSL Behring
- 12.9.1 CSL Behring Company Information
- 12.9.2 CSL Behring Business Overview
- 12.9.3 CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021-2026)
- 12.9.4 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
- 12.9.5 CSL Behring Recent Developments
- 12.10 Kamada Ltd
- 12.10.1 Kamada Ltd Company Information
- 12.10.2 Kamada Ltd Business Overview
- 12.10.3 Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021-2026)
- 12.10.4 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
- 12.10.5 Kamada Ltd Recent Developments
- 12.11 Chiesi Pharmaceuticals
- 12.11.1 Chiesi Pharmaceuticals Company Information
- 12.11.2 Chiesi Pharmaceuticals Business Overview
- 12.11.3 Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021-2026)
- 12.11.4 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
- 12.11.5 Chiesi Pharmaceuticals Recent Developments
- 12.12 Kedrion Group
- 12.12.1 Kedrion Group Company Information
- 12.12.2 Kedrion Group Business Overview
- 12.12.3 Kedrion Group Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021-2026)
- 12.12.4 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
- 12.12.5 Kedrion Group Recent Developments
- 12.13 Vertex Pharmaceuticals
- 12.13.1 Vertex Pharmaceuticals Company Information
- 12.13.2 Vertex Pharmaceuticals Business Overview
- 12.13.3 Vertex Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021-2026)
- 12.13.4 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
- 12.13.5 Vertex Pharmaceuticals Recent Developments
- 12.14 ProMetic Life Sciences
- 12.14.1 ProMetic Life Sciences Company Information
- 12.14.2 ProMetic Life Sciences Business Overview
- 12.14.3 ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021-2026)
- 12.14.4 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
- 12.14.5 ProMetic Life Sciences Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst